Lumacaftor/ivacaftor

Red

Brand Name(s):Orkambi

Indication:Cystic Fibrosis in people 12 years and older who are homozygous for the F508del mutation.

Rationale:1,2,3

Considered:Jul-16

Review Date:Apr-26

Comments:
NHS England has confirmed that ivacaftor, tezacaftor/ivacaftor and elexacaftor/tezacaftor/ivacaftor will be made available as treatment options for people with cystic fibrosis who have one of an expanded range of CFTR mutations within the set criteria.
NHS England commissioning statement.
March ’21.

NICE TA 398
Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
July 2016